Secular Trends in Patent Ductus Arteriosus Management in Infants Born Preterm in the National Institute of Child Health and Human Development Neonatal Research Network

Authors

• Dinushan C Kaluarachchi
• Matthew A Rysavy
• Benjamin A Carper
• Valerie Y Chock
• Matthew M Laughon
• Carl H Backes
• Tarah T Colaizy
• Edward F Bell
• Patrick J McNamara

Language

English

Publication Date

3-1-2024

Journal

The Journal of Pediatrics

DOI

10.1016/j.jpeds.2023.113877

PMID

38135028

PMCID

PMC10922632

PubMedCentral® Posted Date

3-1-2025

PubMedCentral® Full Text Version

Author MSS

Abstract

We evaluated changes in patent ductus arteriosus (PDA) diagnosis and treatment from 2012 through 2021 in a network of US academic hospitals. PDA treatment decreased among infants born at 26-28 weeks but not among infants born at 22-25 weeks. Rates of indomethacin use and PDA ligation decreased while acetaminophen use and transcatheter PDA closure increased.

Keywords

Infant, Newborn, Infant, United States, Child, Humans, Ductus Arteriosus, Patent, Infant, Premature, Ibuprofen, National Institute of Child Health and Human Development (U.S.), Indomethacin

Published Open-Access

yes

Recommended Citation

Kaluarachchi, Dinushan C; Rysavy, Matthew A; Carper, Benjamin A; et al., "Secular Trends in Patent Ductus Arteriosus Management in Infants Born Preterm in the National Institute of Child Health and Human Development Neonatal Research Network" (2024). Faculty, Staff and Student Publications. 4243.
https://digitalcommons.library.tmc.edu/uthmed_docs/4243